Evaluation of clinical efficacy of Cresflut

In December 2024, the U.S. Food and Drug Administration FDA officially approved the official launch of an innovative corticotropin-releasing factor1 type receptor antagonist - Crinecerfont , with the trade name Crenessity. Cresflutide canbe used as an adjunct to glucocorticoid replacement therapy, providing a new treatment approach for patients with typical congenital adrenal hyperplasia (CAH). Cresflutide effectively reduces the secretion of adrenocorticotropic hormone (ACTH) by specifically inhibiting the corticotropin-releasing factor 1 receptor, thereby reducing the excessive production of adrenal cortisol and androgens.

For CAH patients, especially those with 21-hydroxylase deficiency, excessive androgen levels are the culprit of many clinical symptoms (including precocious puberty, hirsutism, etc.). The mechanism of action of Cresflut is precisely to address this problem. It can control androgen levels more accurately while reducing dependence on glucocorticoids, thereby reducing the risk of side effects caused by long-term use of glucocorticoids.

Crisflutide has demonstrated significant efficacy in multiple clinical trials. Taking a phase III clinical trial for CAH patients aged 4 years and above as an example, after 12 weeks of treatment, the patient's androstenedione (an androgen precursor) level was significantly reduced, and the dose of glucocorticoids was also reduced. In addition, the patient's clinical symptoms such as hirsutism and irregular menstruation have also improved. It is worth mentioning that the efficacy of crisflutide has been proven in both adult and pediatric patients and is well tolerated.

Since its launch in December 2024, Cresflut has gradually accumulated valuable actual data in clinical practice. Early use feedback shows that most patients have effectively controlled androgen levels and reduced the dose of glucocorticoids after using Cresflutide, thus alleviating the side effects (such as osteoporosis, weight gain, etc.) caused by long-term use of glucocorticoids. Of course, some patients have reported mild to moderate adverse reactions, such as fatigue, headache, joint pain, etc., but these symptoms usually gradually reduce as treatment progresses.

However, although crisflutide brings new therapeutic hope toCAHpatients, its use still needs to be treated with caution. For4Its safety and effectiveness have not been confirmed and therefore its use is not recommended for children under 10 years of age. At the same time, patients still need to continue using glucocorticoids during treatment to avoid the risk of acute adrenal insufficiency. In addition, some patients may experience allergic reactions (such as throat tightness, rash, etc.). Once such symptoms occur, they should stop taking the medicine and seek medical advice immediately.

In general, Cresflutide has shown significant efficacy in controlling androgen levels inCAHpatients and is expected to reduce the dosage of glucocorticoids, thereby improving the quality of life of patients. However, its long-term efficacy and safety still require further observation and research. For CAH patients, crisflutide is undoubtedly a promising treatment option, but it should be used rationally under the guidance of a doctor and pay close attention to possible side effects. It is believed that as more clinical data accumulates, Cresflut will bring good news to more patients.

Reference link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218808s000,218820s000lbl.pdf